Aspergillosis
📧 Sign up to get email alerts when something new happens for Aspergillosis.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-07-22EMA Authorised: Voriconazole Accord (voriconazole) — Accord Healthcare S.L.U.
The EMA authorised Voriconazole Accord (voriconazole) for treatment of fungal infections including Aspergillosis, Candidiasis, and Mycoses, …
-
EMA approval · 2026-07-21EMA Authorised: Vfend (voriconazole) — Pfizer Europe MA EEIG
Pfizer's voriconazole (Vfend) has been authorised by EMA for use in fungal infections including candidiasis, mycoses, and aspergillosis.
-
EMA approval · 2026-07-01EMA Authorised: Noxafil (posaconazole) — Merck Sharp and Dohme B.V
EMA authorises Noxafil (posaconazole) for multiple fungal infections including candidiasis, mycoses, coccidioidomycosis, and aspergillosis.
-
EMA approval · 2026-06-12EMA Authorised: Posaconazole Accord (posaconazole) — Accord Healthcare S.L.U.
Authorised status for Posaconazole Accord, MAH Accord Healthcare S.L.U., in the therapeutic area of mycoses.
-
EMA approval · 2026-04-28EMA Authorised: Vfend (voriconazole) — Pfizer Europe MA EEIG
European Medicines Agency authorises Vfend (voriconazole) for fungal infections including candidiasis, mycoses, and aspergillosis.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-04-22EMA Authorised: Noxafil (posaconazole) — Merck Sharp and Dohme B.V
The EMA has granted marketing authorization for Noxafil (posaconazole) by Merck Sharp & Dohme B.V. for the treatment and prevention of funga…
-
EMA approval · 2026-04-14EMA Authorised: Vfend (voriconazole) — Pfizer Europe MA EEIG
The European Medicines Agency authorised Vfend (voriconazole) for fungal infections including candidiasis and aspergillosis.
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation [Phase 3]
Phase 3 trial evaluating rezafungin versus standard antimicrobial prophylaxis to prevent invasive fungal diseases in adults undergoing allog…
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: Post Marketing Surveillance (PMS) Study of Cresemba in Korea.
A post-marketing surveillance study of Cresemba (isavuconazole) in Korea has completed, evaluating safety and usage in patients with aspergi…
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: Aspergillus Infection in Patients Admitted to Hematology Ward
A clinical trial is currently recruiting hematology patients to study treatment options for Aspergillosis.
-
EMA approval · 2026-01-08EMA Authorised: Cancidas (previously Caspofungin MSD) (caspofungin (as acetate))
EMA has authorised Cancidas (caspofungin acetate) for the treatment of candidiasis and aspergillosis.
-
CLINICAL_TRIALS trial_result · 2026-01-06Clinical Trial Update: Pharmacokinetics of Voriconazole in Adult ECMO Patients
This completed clinical trial reports on the pharmacokinetics of voriconazole in adult ECMO patients, aiming to inform dosing in this high-r…
-
EMA approval · 2026-01-06EMA Authorised: Voriconazole Hikma (previously Voriconazole Hospira) (voriconazole) — Hikma Farmaceutica (Portugal) S.A.
The EMA authorised Voriconazole Hikma for fungal infections, including aspergillosis and candidiasis, with Hikma Farmaceutica (Portugal) S.A…
-
CLINICAL_TRIALS research · 2025-12-09Clinical Trial Update: PTX3-targeted Antifungal Prophylaxis [NA]
A clinical trial is recruiting to evaluate PTX3-targeted antifungal prophylaxis for preventing candidiasis and other fungal infections, incl…
-
CLINICAL_TRIALS trial_result · 2025-11-20Clinical Trial Update: PET/CT Guided Antifungal Stewardship in Invasive Pulmonary Aspergillosis [NA]
A completed clinical trial evaluating PET/CT-guided antifungal stewardship for invasive pulmonary aspergillosis in patients with hematologic…
-
EMA approval · 2025-10-21EMA Authorised: Voriconazole Accord (voriconazole) — Accord Healthcare S.L.U.
The European Medicines Agency authorised Voriconazole Accord (voriconazole) for treating aspergillosis, candidiasis and other mycoses; the m…
-
EMA approval · 2025-07-24EMA Authorised: Cresemba (isavuconazole) — Basilea Pharmaceutica Deutschland GmbH
The EMA has authorised Cresemba (isavuconazole) for use in Aspergillosis under Basilea Pharmaceutica Deutschland GmbH, with orphan designati…
-
FDA approval · 2025-06-02FDA Approved: AMPHOTERICIN B — Original Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
FDA approved an original application for Amphotericin B as a generic drug by Heritage Pharmaceuticals (Avet) to treat serious systemic funga…
-
CLINICAL_TRIALS research · 2025-05-23Clinical Trial Update: AspergillusOne-Health: Deciphering Azole Resistance in Aspergillus Fungi Using a One Health Approach
This clinical trial aims to understand azole resistance in Aspergillus fumigatus using a One Health approach and is not yet recruiting.
-
CLINICAL_TRIALS trial_result · 2025-04-02Clinical Trial Update: Prospective Observational Study on the Incidence of Opportunistic Fungal Infections
Completed prospective observational study assessing the incidence of opportunistic fungal infections, including Pneumocystis jirovecii pneum…
-
FDA approval · 2025-03-12FDA Approved: ITRACONAZOLE — Supplemental Application (Ascend Laboratories, LLC)
FDA approved a supplemental application for itraconazole from Ascend Laboratories, LLC, authorizing changes to the generic product under AND…
-
CLINICAL_TRIALS research · 2025-03-03Clinical Trial Update: Interferon-gamma as Adjunctive Therapy in Chronic Pulmonary Aspergillosis: a Randomised Feasibility Study [Phase 2]
This is a Phase 2 randomized feasibility trial evaluating interferon-gamma as adjunctive therapy for chronic pulmonary aspergillosis, curren…
-
CLINICAL_TRIALS trial_result · 2025-02-17Clinical Trial Update: Posaconazole Prophylaxis for CAPA Prevention in Critically-Ill Patients
A completed clinical trial evaluating posaconazole prophylaxis to prevent COVID-19-associated pulmonary aspergillosis (CAPA) in critically i…
-
EMA guidance · 2025-01-30One Health: EU agencies unite to tackle azole fungicide resistance in Aspergillus fungi
EU health and environment agencies warn that agricultural use of azole fungicides may drive resistance in Aspergillus fungi, potentially red…
-
FDA approval · 2025-01-29FDA Approved: ITRACONAZOLE — Supplemental Application (Camber Pharmaceuticals, Inc.)
FDA approved a supplemental application for itraconazole by Camber Pharmaceuticals, expanding/updating labeling for the generic product.